Published in Nature on May 02, 2012
The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med (2016) 2.31
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci (2013) 1.29
Handedness and language learning disability differentially distribute in progressive aphasia variants. Brain (2013) 1.13
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Circadian clocks and neurodegenerative diseases: time to aggregate? Curr Opin Neurobiol (2013) 1.07
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02
Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. PLoS One (2012) 1.02
Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci (2013) 1.01
NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis (2013) 0.98
Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem (2014) 0.95
Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol (2013) 0.93
Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. J Cell Biol (2015) 0.93
Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep (2013) 0.93
Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol Aging (2014) 0.91
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol (2014) 0.90
Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener (2012) 0.88
Structures of oligomers of a peptide from β-amyloid. J Am Chem Soc (2013) 0.87
Expanding the repertoire of amyloid polymorphs by co-polymerization of related protein precursors. J Biol Chem (2013) 0.87
Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research. Exp Transl Stroke Med (2012) 0.86
Alzheimer disease: a tale of two prions. Prion (2012) 0.86
Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid β-protein. J Mol Biol (2013) 0.86
Extracellular vesicles in Alzheimer's disease: friends or foes? Focus on aβ-vesicle interaction. Int J Mol Sci (2015) 0.85
Therapies for human prion diseases. Am J Neurodegener Dis (2013) 0.85
Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis (2014) 0.84
Neurofibrillary tangles and the deposition of a beta amyloid peptide with a novel N-terminal epitope in the brains of wild Tsushima leopard cats. PLoS One (2012) 0.84
Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis (2014) 0.83
Assessing the causes and consequences of co-polymerization in amyloid formation. Prion (2013) 0.83
Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores. J Phys Chem B (2014) 0.83
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy. Curr Neuropharmacol (2013) 0.83
The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. J Neurochem (2015) 0.83
The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo) (2012) 0.82
Polymorphism of oligomers of a peptide from β-amyloid. J Am Chem Soc (2014) 0.82
Tau: The Center of a Signaling Nexus in Alzheimer's Disease. Front Neurosci (2016) 0.81
Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice. ACS Chem Neurosci (2013) 0.81
A fibril-like assembly of oligomers of a peptide derived from β-amyloid. J Am Chem Soc (2014) 0.81
Role of the fast kinetics of pyroglutamate-modified amyloid-β oligomers in membrane binding and membrane permeability. Biochemistry (2014) 0.81
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice. Neurobiol Aging (2015) 0.81
Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener (2014) 0.80
Prions and prion-like pathogens in neurodegenerative disorders. Pathogens (2014) 0.80
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener (2016) 0.80
Context dependence of protein misfolding and structural strains in neurodegenerative diseases. Biopolymers (2013) 0.80
Insights into the consequences of co-polymerisation in the early stages of IAPP and Aβ peptide assembly from mass spectrometry. Analyst (2015) 0.79
Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. J Biol Chem (2015) 0.79
Molecular and genetic inflammation networks in major human diseases. Mol Biosyst (2016) 0.79
Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. BMC Neurosci (2013) 0.79
Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. Int J Cell Biol (2013) 0.79
Pyroglutamylated amyloid-β peptide reverses cross β-sheets by a prion-like mechanism. J Phys Chem B (2014) 0.79
BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer's disease. Neural Regen Res (2016) 0.78
Linked production of pyroglutamate-modified proteins via self-cleavage of fusion tags with TEV protease and autonomous N-terminal cyclization with glutaminyl cyclase in vivo. PLoS One (2014) 0.78
The neurodegeneration in Alzheimer disease and the prion protein. Prion (2013) 0.78
Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid-β-induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. J Biol Chem (2015) 0.78
Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloid. Neurobiol Dis (2015) 0.78
Tau and neuron aging. Aging Dis (2012) 0.78
Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Biochim Biophys Acta (2014) 0.78
Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Sci Rep (2016) 0.78
Amyloid-Beta Induced Changes in Vesicular Transport of BDNF in Hippocampal Neurons. Neural Plast (2016) 0.77
A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. J Biol Chem (2016) 0.77
Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion. Neurodegener Dis (2014) 0.77
Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease. Neurobiol Aging (2016) 0.77
β-hairpin-mediated formation of structurally distinct multimers of neurotoxic prion peptides. PLoS One (2014) 0.76
Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides. Phys Chem Chem Phys (2015) 0.76
Alzheimer's disease and prion protein. Intractable Rare Dis Res (2013) 0.76
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease. Acta Neuropathol (2015) 0.76
Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol (2016) 0.76
Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun (2017) 0.75
Familial Alzheimer's disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid beta peptide. J Biol Chem (2017) 0.75
The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro. Stem Cell Res Ther (2015) 0.75
Synthesis and evaluation of [(11)C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation. Medchemcomm (2015) 0.75
Phosphorylation at Ser 8 as an Intrinsic Regulatory Switch to Regulate the Morphologies and Structures of Alzheimer's 40-residue β-Amyloid (Aβ40) Fibrils. J Biol Chem (2016) 0.75
Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathol (2016) 0.75
pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity. Acta Neuropathol Commun (2016) 0.75
Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. Neurobiol Dis (2015) 0.75
Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics. Nanomedicine (2016) 0.75
A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides. Mol Med (2016) 0.75
Fibrils of Truncated Pyroglutamyl-Modified Aβ Peptide Exhibit a Similar Structure as Wildtype Mature Aβ Fibrils. Sci Rep (2016) 0.75
Pyroglutamyl-N-terminal prion protein fragments in sheep brain following the development of transmissible spongiform encephalopathies. Front Mol Biosci (2015) 0.75
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy. J Biol Chem (2017) 0.75
Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers. Chem Sci (2017) 0.75
Human TAU(P301L) overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. Sci Rep (2017) 0.75
Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in Tau(-/-) mice. Front Neurosci (2017) 0.75
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci (1993) 7.92
Neurotrophins are required for nerve growth during development. Nat Neurosci (2001) 3.96
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Tau reduction prevents Abeta-induced defects in axonal transport. Science (2010) 2.57
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem (1992) 2.26
Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res (2001) 2.04
High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience (2006) 2.03
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry (2006) 1.72
Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci (2008) 1.64
beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem (2005) 1.48
Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J Neurochem (2002) 1.46
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry (1999) 1.37
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol (1993) 1.32
Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun (1994) 1.27
Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry (2009) 1.25
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem (2011) 1.23
Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem (2010) 1.16
Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci (2011) 1.08
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. Int J Alzheimers Dis (2010) 0.98
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol (2011) 0.95
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 4.33
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol (2006) 3.72
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest (2011) 2.58
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats. J Neurosci (2004) 2.50
Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res (2005) 2.45
Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol (2006) 2.43
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun (2002) 2.28
Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem (2003) 2.24
Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet (2004) 2.23
Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A (2007) 2.13
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem (2006) 2.09
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
Dual control of caveolar membrane traffic by microtubules and the actin cytoskeleton. J Cell Sci (2002) 1.87
IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Circ Res (2004) 1.85
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: a new mechanism of CNS immune privilege. J Neurosci (2008) 1.73
Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol (2006) 1.72
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry (2006) 1.72
Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. Genes Dev (2004) 1.64
The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A (2003) 1.62
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem (2008) 1.56
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Prospective outcome study of 360 patients treated with liposuction, lipoabdominoplasty, and abdominoplasty. Plast Reconstr Surg (2012) 1.54
Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes (2002) 1.54
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Interactions between the NR2B receptor and CaMKII modulate synaptic plasticity and spatial learning. J Neurosci (2007) 1.51
IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. J Cell Sci (2007) 1.49
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49
Overexpression of wild-type heat shock protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation (2004) 1.47
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci (2005) 1.44
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
The mechanism for regulation of the F-actin binding activity of IQGAP1 by calcium/calmodulin. J Biol Chem (2002) 1.44
Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43
Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci U S A (2010) 1.42
Textured Breast Implants, Anaplastic Large-Cell Lymphoma, and Conflict of Interest. Plast Reconstr Surg (2017) 1.40
Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A (2012) 1.39
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 1.37
Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest (2014) 1.37
A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci (2009) 1.36
The Ruth Graf technique: measurements do not support the efficacy of an inferior pedicle and pectoralis muscle loop in mammaplasty. Plast Reconstr Surg (2013) 1.34
Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity (2005) 1.33
Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol (2009) 1.33
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept (2005) 1.32
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett (2004) 1.30
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Cytoskeletal pathologies of Alzheimer disease. Cell Motil Cytoskeleton (2009) 1.28
ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem (2006) 1.28
MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet (2003) 1.26
Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry (2009) 1.25
HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Arthritis Rheum (2002) 1.24
Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 1.24
IQGAPs: integrators of the cytoskeleton, cell adhesion machinery, and signaling networks. Cell Motil Cytoskeleton (2003) 1.24
CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice. J Neurosci (2011) 1.22
Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. Biol Chem (2008) 1.20
An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice. J Clin Invest (2007) 1.20
Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci (2009) 1.18
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry (2008) 1.18
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun (2007) 1.17
Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res (2006) 1.17
Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem (2010) 1.16
Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci (2005) 1.16
Actin filament binding by a monomeric IQGAP1 fragment with a single calponin homology domain. Cell Motil Cytoskeleton (2004) 1.16
Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res (2005) 1.16
Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology (2003) 1.13
Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2007) 1.12
Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med (2007) 1.12
A luminous efficiency function, V*(lambda), for daylight adaptation. J Vis (2005) 1.12
Reducing venous thromboembolism risk without chemoprophylaxis. Plast Reconstr Surg (2013) 1.11
Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol (2004) 1.08
Nipple sensation losses in Hall-Findlay breast reduction technique. Plast Reconstr Surg (2013) 1.08
The plastic surgeon: artist or scientist? Plast Reconstr Surg (2013) 1.08
Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci (2011) 1.08